Ranjan Pai is among India’s most influential investors. So, when he makes a move into senior care, it is time to sit up and take notice of the sector, not to mention the broader grey economy.
Related Posts
Lifesaver to litigant: how a Covid-19 drug drove a wedge between Max Healthcare and Novacare
Synopsis Ronapreve came as a boon at the peak of the Delta wave in 2021. But as the injection turned…
How a scientist at Enzene is rethinking manufacturing to make anti-cancer drugs affordable in India
Himanshu Gadgil, CEO, Enzene Biosciences; Enzene Biosciences in Pune; image credit: Enzene Synopsis Anti-cancer drugs are beyond the reach of…
Redcliffe Labs is taking on incumbents like Dr Lal PathLabs. But is it biting more than it can chew?
Dheeraj Jain, founder and MD, Redcliffe Labs; image credit: Redcliffe Labs Synopsis Having set itself a target to reach INR5,000…